BofA analyst Greg Harrison downgraded Graphite Bio to Neutral from Buy with a price target of $3, down from $7, after the company announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRPH:
- Graphite Bio price target lowered to $4 from $11 at RBC Capital
- Graphite Bio downgraded to Market Perform from Outperform at SVB Securities
- Graphite Bio downgraded to Market Perform from Outperform at BMO Capital
- Graphite Bio to voluntarily pause Phase 1/2 CEDAR study
- Graphite Bio price target lowered to $8 from $10 at BofA
